Oppenheimer Remains a Buy on Vascular Biogenics (VBLT)


In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vascular Biogenics (VBLT), with a price target of $2.50. The company’s shares closed last Wednesday at $1.97, close to its 52-week high of $2.06.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 52.0% and a 58.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Vascular Biogenics is a Strong Buy with an average price target of $3.08.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.06 and a one-year low of $0.90. Currently, Vascular Biogenics has an average volume of 248.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts